UK NHS Pharmaceutical Approval Body Rejects GSK’s Lupus Drug Benlysta
Abstract:GSK’s new medicine for treating Lupus – Benlysta (generically known as ‘Belimubab’) was rejected by the UK National Health Service’s (NHS) drug rationing body. The drug was discovered by Human Genome Sciences and developed by Glaxo SmithKline (GSK) to combat the disease that causes the immune system to attack joints and organs. This article details why the drug was rejected and outlines the NHS drug approval process.
Trending Compliance Trainings
Sterile Filtration of Pharmaceutical Products - Validation and Regulatory Requirements
By - Roger Cowan
On Demand Access Anytime
By - Roger Cowan
On Demand Access Anytime
FFIEC BSA/AML Examination Manual: What Compliance Officers Really Need to Know?
By - Doug Keipper
On Demand Access Anytime
By - Doug Keipper
On Demand Access Anytime
Technical Writing for the Pharmaceutical, Medical Device and Biotech Industries
By - Joy McElroy
On Demand Access Anytime
By - Joy McElroy
On Demand Access Anytime
Trial Master File and Clinical Data Management Regulated by FDA
By - Carolyn Troiano
On Demand Access Anytime
By - Carolyn Troiano
On Demand Access Anytime
Good Documentation Practice and Record Keeping Regulations (FDA & EMA)
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
Understanding and Preparing for FDA Pharmaceutical Inspections
By - Michael Ferrante
On Demand Access Anytime
By - Michael Ferrante
On Demand Access Anytime
You Recently Viewed
